330 related articles for article (PubMed ID: 31528982)
1. Renal transplant patients with preformed anti-HLA antibodies: early biopsy findings and clinical outcomes.
Sousa MV; Zollner RL; Mazzali M
J Bras Nefrol; 2019 Sep; 42(2):201-210. PubMed ID: 31528982
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance of the presence of anti-human leukocyte antigen-donor specific antibody in kidney transplant recipients with allograft dysfunction.
Chung BH; Kim JH; Choi BS; Park CW; Kim JI; Moon IS; Kim YS; Choi YJ; Oh EJ; Yang CW
Korean J Intern Med; 2018 Jan; 33(1):157-167. PubMed ID: 27764540
[TBL] [Abstract][Full Text] [Related]
3. Development of de novo HLA donor specific antibodies (HLA-DSA), HLA antibodies (HLA-Ab) and allograft rejection post blood transfusion in kidney transplant recipients.
Jalalonmuhali M; Carroll RP; Tsiopelas E; Clayton P; Coates PT
Hum Immunol; 2020 Jul; 81(7):323-329. PubMed ID: 32327243
[TBL] [Abstract][Full Text] [Related]
4. Post-transplant donor specific antibody is associated with poor kidney transplant outcomes only when combined with both T-cell-mediated rejection and non-adherence.
Cherukuri A; Mehta R; Sharma A; Sood P; Zeevi A; Tevar AD; Rothstein DM; Hariharan S
Kidney Int; 2019 Jul; 96(1):202-213. PubMed ID: 31029504
[TBL] [Abstract][Full Text] [Related]
5. Preformed donor-specific antibodies and risk of antibody-mediated rejection in repeat renal transplantation.
Tsapepas DS; Vasilescu R; Tanriover B; Coppleson Y; Rekhtman Y; Hardy MA; Dube G; Crew RJ; Ratner LE; Cohen DJ; Mohan S
Transplantation; 2014 Mar; 97(6):642-7. PubMed ID: 24637863
[TBL] [Abstract][Full Text] [Related]
6. Effect of Preformed or De Novo Anti-HLA Antibodies on Function and Graft Survival in Kidney Transplant Recipients.
de Sousa MV; Gonçalez AC; Zollner RL; Mazzali M
Ann Transplant; 2018 Jul; 23():457-466. PubMed ID: 29976918
[TBL] [Abstract][Full Text] [Related]
7. Non-HLA agonistic anti-angiotensin II type 1 receptor antibodies induce a distinctive phenotype of antibody-mediated rejection in kidney transplant recipients.
Lefaucheur C; Viglietti D; Bouatou Y; Philippe A; Pievani D; Aubert O; Duong Van Huyen JP; Taupin JL; Glotz D; Legendre C; Loupy A; Halloran PF; Dragun D
Kidney Int; 2019 Jul; 96(1):189-201. PubMed ID: 31005275
[TBL] [Abstract][Full Text] [Related]
8. Characteristics of donor-specific anti-HLA antibodies and outcome in renal transplant patients treated with a standardized induction regimen.
Zecher D; Bach C; Staudner C; Böger CA; Bergler T; Banas B; Spriewald BM
Nephrol Dial Transplant; 2017 Apr; 32(4):730-737. PubMed ID: 28339671
[TBL] [Abstract][Full Text] [Related]
9. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
Zheng J; Xue W; Qing X; Jing X; Hou J; Tian X; Guo Q; He X; Cai J
Clin Transpl; 2014; ():223-30. PubMed ID: 26281149
[TBL] [Abstract][Full Text] [Related]
10. Circulating donor-specific anti-HLA antibodies are a major factor in premature and accelerated allograft fibrosis.
Gosset C; Viglietti D; Rabant M; Vérine J; Aubert O; Glotz D; Legendre C; Taupin JL; Duong Van-Huyen JP; Loupy A; Lefaucheur C
Kidney Int; 2017 Sep; 92(3):729-742. PubMed ID: 28554738
[TBL] [Abstract][Full Text] [Related]
11. Donor-Specific Anti-Human Leukocyte Antigens Antibodies, Acute Rejection, Renal Function, and Histology in Kidney Transplant Recipients Receiving Tacrolimus and Everolimus.
Ferreira A; Felipe C; Cristelli M; Viana L; Basso G; Stopa S; Mansur J; Ivani M; Bessa A; Ruppel P; Aguiar W; Campos E; Gerbase-DeLima M; Proença H; Tedesco-Silva H; Medina-Pestana J
Am J Nephrol; 2017; 45(6):497-508. PubMed ID: 28511172
[TBL] [Abstract][Full Text] [Related]
12. Conversion From Calcineurin Inhibitors to Belatacept in HLA-sensitized Kidney Transplant Recipients With Low-level Donor-specific Antibodies.
Ulloa CE; Anglicheau D; Snanoudj R; Scemla A; Martinez F; Timsit MO; Legendre C; Sberro-Soussan R
Transplantation; 2019 Oct; 103(10):2150-2156. PubMed ID: 30720681
[TBL] [Abstract][Full Text] [Related]
13. Pretransplant C3d-Fixing Donor-Specific Anti-HLA Antibodies Are Not Associated with Increased Risk for Kidney Graft Failure.
Kamburova EG; Wisse BW; Joosten I; Allebes WA; van der Meer A; Hilbrands LB; Baas MC; Spierings E; Hack CE; van Reekum FE; van Zuilen AD; Verhaar MC; Bots ML; Drop ACAD; Plaisier L; Seelen MAJ; Sanders JS; Hepkema BG; Lambeck AJA; Bungener LB; Roozendaal C; Tilanus MGJ; Voorter CE; Wieten L; van Duijnhoven EM; Gelens MACJ; Christiaans MHL; van Ittersum FJ; Nurmohamed SA; Lardy NM; Swelsen W; van der Pant KAMI; van der Weerd NC; Ten Berge IJM; Bemelman FJ; Hoitsma AJ; van der Boog PJM; de Fijter JW; Betjes MGH; Heidt S; Roelen DL; Claas FH; Otten HG
J Am Soc Nephrol; 2018 Sep; 29(9):2279-2285. PubMed ID: 30049681
[No Abstract] [Full Text] [Related]
14. Frequency of Human Leukocyte Antigens and Donor Specific Antibodies in Long-Term Living Donor Kidney Transplantation.
Alagoz S; Seyahi N
Transplant Proc; 2019 Sep; 51(7):2302-2307. PubMed ID: 31358448
[TBL] [Abstract][Full Text] [Related]
15. Subclinical Lesions and Donor-Specific Antibodies in Kidney Transplant Recipients Receiving Tacrolimus-Based Immunosuppressive Regimen Followed by Early Conversion to Sirolimus.
de Sandes-Freitas TV; Felipe CR; Campos ÉF; de Lima MG; Soares MF; de Franco MF; Aguiar WF; Tedesco-Silva H; Medina-Pestana JO
Transplantation; 2015 Nov; 99(11):2372-81. PubMed ID: 25929604
[TBL] [Abstract][Full Text] [Related]
16. Graft immunologic events in deceased donor kidney transplant recipients with preformed HLA-donor specific antibodies.
Ixtlapale-Carmona X; Arvizu A; De-Santiago A; González-Tableros N; López M; Castelán N; Marino LA; Uribe-Uribe NO; Contreras AG; Vilatobá M; Morales-Buenrostro LE; Alberú J
Transpl Immunol; 2018 Feb; 46():8-13. PubMed ID: 28974434
[TBL] [Abstract][Full Text] [Related]
17. Association of angiotensin II type 1 receptor antibodies with graft histology, function and survival in paediatric renal transplant recipients.
Fichtner A; Süsal C; Schröder C; Höcker B; Rieger S; Waldherr R; Westhoff JH; Sander A; Dragun D; Tönshoff B
Nephrol Dial Transplant; 2018 Jun; 33(6):1065-1072. PubMed ID: 29444269
[TBL] [Abstract][Full Text] [Related]
18. Influence of preformed donor-specific antibodies and C4d on early liver allograft function.
Perera MT; Silva MA; Murphy N; Briggs D; Mirza DF; Neil DA
Scand J Gastroenterol; 2013 Dec; 48(12):1444-51. PubMed ID: 24131305
[TBL] [Abstract][Full Text] [Related]
19. Analysis of specificity of anti-human leukocyte antigen antibodies in kidney recipients in reference to clinical outcome.
Nowosiad-Magda M; Myślak M; Roszkowska P; Borowiec-Chłopek Z; Urasińska E; Różański J; Domański L; Ciechanowski K; Giedrys-Kalemba S
Transplant Proc; 2014 Oct; 46(8):2606-12. PubMed ID: 25380877
[TBL] [Abstract][Full Text] [Related]
20. Investigation of Serum Angiotensin II Type 1 Receptor Antibodies at the Time of Renal Allograft Rejection.
Lee H; Kim JI; Moon IS; Chung BH; Yang CW; Kim Y; Han K; Oh EJ
Ann Lab Med; 2015 May; 35(3):314-20. PubMed ID: 25932439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
